other material
confidence high
sentiment positive
materiality 0.80
Inhibrx INBRX-106 nearly doubles cORR in Phase 2 HNSCC; PFS 9.6 vs 4.9 months
Inhibrx Biosciences, Inc.
- cORR 48.3% (INBRX-106+pembro) vs 26.5% (pembro alone); CR 13.8% vs 0%.
- Median PFS 9.6 vs 4.9 months; 6-mo PFS 72.4% vs 42.8%.
- HPV+ subgroup: cORR 80% vs 33.3%, CR 30% vs 0%, PFS6 90% vs 33%.
- Plans to expand Phase 2 by ~50 HPV+ OPSCC patients; Phase 3 as confirmatory.
- Combination manageable; common AEs rash, fatigue, diarrhea (low grade).